Share Conference Coverage
Share to email
Share to Facebook
Share to X
By ReachMD
The podcast currently has 269 episodes available.
One of the major changes that's occurred very recently in the field of neurodegenerative disease and Alzheimer's disease, specifically, are the recently approved antibody therapies that remove amyloid from the brain, which is one of the culprit proteins in Alzheimer's disease. To learn more about this presentation from SNMMI 2024, join Dr. Phillip Kuo, Professor of Medical Imaging, Medicine, and Biomedical Engineering at the University of Arizona.
When looking at patients who suffer from prostate cancer who are receiving PSMA therapy, we can see on our images that the medication not only goes to their cancer, but it also goes to some other things in their body, including the salivary glands. To learn more about his recent study on salivary toxicity, join Dr. Geoffrey Johnson, Nuclear Medicine Specialist and Radiologist at the Mayo Clinic in Rochester, Minnesota.
Prostate-specific membrane antigen (PSMA) PET scans are a method by which clinicians can see if a patient who is suffering from prostate cancer has tumors that are expressing the PSMA target. In addition to that, the scan allows us to measure how much of the medication we get onto that cancer target and if it’s going to be effective. Take a deep dive with Dr. Jennifer Caudle as she speaks with Dr. Geoffrey Johnson, Nuclear Medicine Specialist and Radiologist at the Mayo Clinic in Rochester, Minnesota, who also presented this research at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting.
The Discovery Team at Perspective has developed a compound, called PSV-359, which is a cyclic peptide radiopharmaceutical. It targets a protein, called fibroblast activation protein (FAP), which is a pan-cancer target and is expressed in a wide variety of cancers. To learn more about her presentation from SNMMI 2024, hear from Brianna Cagle, Research Scientist at Perspective Therapeutics in Iowa.
The AI landscape is evolving at a rapid pace. However, there is a shortage of large public data sets in nuclear medicine that AI models can be trained on. To learn more about what’s on the AI horizon and the challenges that are associated, join Dr. Joyita Dutta, Associate Professor at the University of Massachusetts, Amherst in the Department of Biomedical Engineering, who also presented this at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting.
The field of artificial intelligence in nuclear medicine is evolving quickly with new models and approaches. Tune in with Dr. Chi Liu, Professor of Radiology and Biomedical Engineering at Yale University, to hear more about his presentation from SNMMI 2024.
Clinicians are hopeful that theranostics could help treat patients as soon as they go metastatic or even before surgery to try to affect their therapy and possibly get them to avoid having to take toxic or high side effect therapies. To hear more, tune in with Dr. Geoffrey Johnson, Nuclear Medicine Specialist and Radiologist at the Mayo Clinic in Rochester, Minnesota.
At the 2024 Digestive Disease Week Annual Meeting, Dr. Bryson Katona presented a session, titled “High-Risk Colon Cancer: The ABCs of Genetic Testing.” And now, Dr. Katona is here with Dr. Jody Takemoto to share key insights from his session on genetic testing for patients with high-risk colon cancer. Dr. Katona is the Director of the Gastrointestinal Cancer Genetics Program and Risk Evaluation Program and the Lynch Syndrome Program at Penn Medicine
With a few studies in the works for cancer vaccines, the future is exciting for what this could mean for oncology patients. Dive in to learn about the various ways to package cancer vaccines so they can be delivered to patients effectively. And to learn more about the limitations, targets, and platforms of cancer vaccines, which was the topic of her presentation at the American Society of Clinical Oncology 2024 Conference, hear from Dr. Lillian Siu, Senior Medical Oncologist at the Princess Margaret Cancer Centre and Professor of Medicine at the University of Toronto.
Since cancer vaccines have been of interest to oncologists for decades, they’ve been trying to figure out how to prime or stimulate the immune system to attack cancer, and until the last few years, cancer vaccines have been challenging. To learn about this unique area of study, which she also presented at ASCO 2024, join Dr. Lillian Siu, Senior Medical Oncologist at the Princess Margaret Cancer Centre and a Professor of Medicine at the University of Toronto.
The podcast currently has 269 episodes available.
3,031 Listeners
55 Listeners